Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 3/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140434 | 1.00 | MAPT (0.47) | MAPTSMN1; SMN2LMNAHTTFASN | |
| SCHEMBL1140675 | 0.91 | MAPK14 (0.53) | MAPTSMN1; SMN2LMNAHTTFASN | |
| SCHEMBL6341234 | 0.91 | MAPK14 (0.53) | MAPTSMN1; SMN2LMNAHTTFASN | |
| SCHEMBL1140511 | 0.91 | SMO (0.57) | ABL1SMOPGRGPR183 | |
| SCHEMBL1140514 | 0.91 | SMO (0.57) | ABL1SMOPGRGPR183 | |
| SCHEMBL16986706 | 0.89 | SMO (0.41) | MAPTSMN1; SMN2LMNAHTTFASN | |
| SCHEMBL1140406 | 0.88 | MAPT (0.62) | MAPTSMN1; SMN2LMNAHTTABL1 | |
| SCHEMBL1140823 | 0.85 | MAPT (0.58) | MAPTSMN1; SMN2LMNAHTTFASN | |
| SCHEMBL1140464 | 0.85 | KCNQ3 (0.56) | MAPTSMN1; SMN2LMNAHTTFASN | |
| SCHEMBL11964542 | 0.81 | SMO (0.67) | MAPTFASNCYP1A2CYP2C19SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | MAPT 4534/4885SMN1; SMN2 3424/4885LMNA 4269/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4520/4885SMN1; SMN2 3605/4885LMNA 4488/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4520/4885SMN1; SMN2 3605/4885LMNA 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.